Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN®)
Bernardete Pessoa,1,2 João Melo-Beirão,1,2 Angelina Meireles,1,2 Pedro Menéres1,2 1Ophtalmology Department, Centro Hospitalar e Universitário do Porto, Porto, Portugal; 2Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Bi...
Main Authors: | Pessoa B, Melo-Beirão J, Meireles A, Menéres P |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-09-01
|
Series: | International Medical Case Reports Journal |
Subjects: | |
Online Access: | https://www.dovepress.com/challenging-clinical-cases-ndash-a-walk-through-supplemental-therapy-w-peer-reviewed-article-IMCRJ |
Similar Items
-
Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
by: William Fusi-Rubiano, et al.
Published: (2018-09-01) -
Clinical utility of intravitreal fluocinolone acetonide (Iluvien®) implant in the management of patients with chronic diabetic macular edema: a review of the current literature
by: Saedon H, et al.
Published: (2017-03-01) -
Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years
by: William Fusi-Rubiano, et al.
Published: (2018-02-01) -
Clinical Effectiveness of Intravitreal Fluocinolone Acetonide (FAc) (ILUVIEN™) in Patients with Diabetic Macular Oedema (DMO) Refractory to Prior Therapy: The Manchester Experience
by: James F. Young, et al.
Published: (2019-07-01) -
Biomarkers to Predict the Success of Treatment with the Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Uveitic Macular Edema
by: Lucy Joanne Kessler, et al.
Published: (2022-03-01)